Health supervision for children with neurofibromatosis type 1

COUNCIL ON GENETICS, AMERICAN COLLEGE OF MEDICAL GENETICS AND GENOMICS

Research output: Contribution to journalReview article

Abstract

Neurofibromatosis type 1 (NF1) is a multisystem disorder that primarily involves the skin and peripheral nervous system. Its population prevalence is approximately 1 in 3000. The condition is usually recognized in early childhood, when pigmentary manifestations emerge. Although NF1 is associated with marked clinical variability, most children affected follow patterns of growth and development within the normal range. Some features of NF1 can be present at birth, but most manifestations emerge with age, necessitating periodic monitoring to address ongoing health and developmental needs and minimize the risk of serious medical complications. In this report, we provide a review of the clinical criteria needed to establish a diagnosis, the inheritance pattern of NF1, its major clinical and developmental manifestations, and guidelines for monitoring and providing intervention to maximize the health and quality of life of a child affected.

Original languageEnglish (US)
Article numberY
JournalPediatrics
Volume143
Issue number5
DOIs
StatePublished - May 1 2019

Fingerprint

Neurofibromatosis 1
Inheritance Patterns
Health
Peripheral Nervous System
Growth and Development
Reference Values
Quality of Life
Parturition
Guidelines
Skin
Child Health
Population

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

COUNCIL ON GENETICS, AMERICAN COLLEGE OF MEDICAL GENETICS AND GENOMICS (2019). Health supervision for children with neurofibromatosis type 1. Pediatrics, 143(5), [Y]. https://doi.org/10.1542/peds.2019-0660

Health supervision for children with neurofibromatosis type 1. / COUNCIL ON GENETICS, AMERICAN COLLEGE OF MEDICAL GENETICS AND GENOMICS.

In: Pediatrics, Vol. 143, No. 5, Y, 01.05.2019.

Research output: Contribution to journalReview article

COUNCIL ON GENETICS, AMERICAN COLLEGE OF MEDICAL GENETICS AND GENOMICS 2019, 'Health supervision for children with neurofibromatosis type 1', Pediatrics, vol. 143, no. 5, Y. https://doi.org/10.1542/peds.2019-0660
COUNCIL ON GENETICS, AMERICAN COLLEGE OF MEDICAL GENETICS AND GENOMICS. Health supervision for children with neurofibromatosis type 1. Pediatrics. 2019 May 1;143(5). Y. https://doi.org/10.1542/peds.2019-0660
COUNCIL ON GENETICS, AMERICAN COLLEGE OF MEDICAL GENETICS AND GENOMICS. / Health supervision for children with neurofibromatosis type 1. In: Pediatrics. 2019 ; Vol. 143, No. 5.
@article{ca0deb3333164cc6a0e4152240cf79c1,
title = "Health supervision for children with neurofibromatosis type 1",
abstract = "Neurofibromatosis type 1 (NF1) is a multisystem disorder that primarily involves the skin and peripheral nervous system. Its population prevalence is approximately 1 in 3000. The condition is usually recognized in early childhood, when pigmentary manifestations emerge. Although NF1 is associated with marked clinical variability, most children affected follow patterns of growth and development within the normal range. Some features of NF1 can be present at birth, but most manifestations emerge with age, necessitating periodic monitoring to address ongoing health and developmental needs and minimize the risk of serious medical complications. In this report, we provide a review of the clinical criteria needed to establish a diagnosis, the inheritance pattern of NF1, its major clinical and developmental manifestations, and guidelines for monitoring and providing intervention to maximize the health and quality of life of a child affected.",
author = "{COUNCIL ON GENETICS, AMERICAN COLLEGE OF MEDICAL GENETICS AND GENOMICS} and Miller, {David T.} and Debra Freedenberg and Elizabeth Schorry and Ullrich, {Nicole J.} and David Viskochil and Korf, {Bruce R.} and Emily Chen and Trotter, {Tracy L.} and Berry, {Susan A.} and Burke, {Leah W.} and Geleske, {Timothy A.} and Rizwan Hamid and Hopkin, {Robert J.} and Introne, {Wendy J.} and Lyons, {Michael J.} and Angela Scheuerle and Stoler, {Joan M.}",
year = "2019",
month = "5",
day = "1",
doi = "10.1542/peds.2019-0660",
language = "English (US)",
volume = "143",
journal = "Pediatrics",
issn = "0031-4005",
publisher = "American Academy of Pediatrics",
number = "5",

}

TY - JOUR

T1 - Health supervision for children with neurofibromatosis type 1

AU - COUNCIL ON GENETICS, AMERICAN COLLEGE OF MEDICAL GENETICS AND GENOMICS

AU - Miller, David T.

AU - Freedenberg, Debra

AU - Schorry, Elizabeth

AU - Ullrich, Nicole J.

AU - Viskochil, David

AU - Korf, Bruce R.

AU - Chen, Emily

AU - Trotter, Tracy L.

AU - Berry, Susan A.

AU - Burke, Leah W.

AU - Geleske, Timothy A.

AU - Hamid, Rizwan

AU - Hopkin, Robert J.

AU - Introne, Wendy J.

AU - Lyons, Michael J.

AU - Scheuerle, Angela

AU - Stoler, Joan M.

PY - 2019/5/1

Y1 - 2019/5/1

N2 - Neurofibromatosis type 1 (NF1) is a multisystem disorder that primarily involves the skin and peripheral nervous system. Its population prevalence is approximately 1 in 3000. The condition is usually recognized in early childhood, when pigmentary manifestations emerge. Although NF1 is associated with marked clinical variability, most children affected follow patterns of growth and development within the normal range. Some features of NF1 can be present at birth, but most manifestations emerge with age, necessitating periodic monitoring to address ongoing health and developmental needs and minimize the risk of serious medical complications. In this report, we provide a review of the clinical criteria needed to establish a diagnosis, the inheritance pattern of NF1, its major clinical and developmental manifestations, and guidelines for monitoring and providing intervention to maximize the health and quality of life of a child affected.

AB - Neurofibromatosis type 1 (NF1) is a multisystem disorder that primarily involves the skin and peripheral nervous system. Its population prevalence is approximately 1 in 3000. The condition is usually recognized in early childhood, when pigmentary manifestations emerge. Although NF1 is associated with marked clinical variability, most children affected follow patterns of growth and development within the normal range. Some features of NF1 can be present at birth, but most manifestations emerge with age, necessitating periodic monitoring to address ongoing health and developmental needs and minimize the risk of serious medical complications. In this report, we provide a review of the clinical criteria needed to establish a diagnosis, the inheritance pattern of NF1, its major clinical and developmental manifestations, and guidelines for monitoring and providing intervention to maximize the health and quality of life of a child affected.

UR - http://www.scopus.com/inward/record.url?scp=85065509866&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065509866&partnerID=8YFLogxK

U2 - 10.1542/peds.2019-0660

DO - 10.1542/peds.2019-0660

M3 - Review article

C2 - 31010905

AN - SCOPUS:85065509866

VL - 143

JO - Pediatrics

JF - Pediatrics

SN - 0031-4005

IS - 5

M1 - Y

ER -